| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| PD, PK, and Safety of ALTO-203 in Patients With MDDNCT06391593 | Alto Neuroscience | Phase 2 | Completed | 2025-04-14Actual |
| Phase III Study of AK112 for NSCLC PatientsNCT06396065 | Summit Therapeutics | Phase 3 | Active not recruiting | 2025-04-12Actual |
| Study That Tests AD109 in Patients Taking GLP-1 DrugsNCT06400615 | Apnimed | Phase 2 | Completed | 2024-12-26Actual |
| A Strain Change Study for SARS-CoV-2 rS VaccinesNCT06409663 | Novavax | Phase 3 | Completed | 2024-10-15Actual |
| Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis SuppurativaNCT06411379 | MoonLake Immunotherapeutics AG | Phase 3 | Completed | 2025-08-14Actual |
| A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis SuppurativaNCT06411899 | MoonLake Immunotherapeutics AG | Phase 3 | Completed | 2025-09-02Actual |
| A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).NCT06412666 | Cytokinetics | Phase 2, Phase 3 | Active not recruiting | 2030-01Estimated |
| Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using SolriamfetolNCT06413433 | AXSM | Phase 3 | Recruiting | 2026-12Estimated |
| Long-term Extension of GTX-102 in Angelman SyndromeNCT06415344 | RARE | Phase 3 | Terminated | 2026-10-30Actual |
| ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation SuspensionNCT06418711 | Mannkind Corporation | Phase 3 | Terminated | 2025-11-10Actual |
| A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3GNCT06419205 | Akebia Therapeutics | Phase 2 | Recruiting | 2028-02Estimated |
| OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi SyndromeNCT06420297 | ACAD | Phase 3 | Terminated | 2025-12-19Actual |
| Clinical Trial to Evaluate the Efficacy of Gene Therapy for Pyruvate Kinase DeficiencyNCT06422351 | RCKT | Phase 2 | Suspended | 2029-01Estimated |
| Study of Olverembatinib (HQP1351) in Patients With CML-CPNCT06423911 | Ascentage Pharma Group Inc. | Phase 3 | Recruiting | 2027-06-30Estimated |
| A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye DiseaseNCT06424444 | ALDX | Phase 3 | Completed | 2024-11-03Actual |
| To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.NCT06429722 | NMRA | Phase 2 | Completed | 2025-04-09Actual |
| ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)NCT06430385 | IONS | Phase 1, Phase 2 | Recruiting | 2027-09Estimated |
| Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).NCT06431776 | SVRA | Phase 3 | Recruiting | 2027-06Estimated |
| A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE) (ENSEMBLE)NCT06431893 | TVTX | Phase 3 | Enrolling by invitation | 2030-08Estimated |
| Safety Study of Cytisinicline in Adult Combustible and/or E-cigarette SmokersNCT06435221 | Achieve Life Sciences | Phase 3 | Completed | 2025-09-29Actual |
| A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast CancerNCT06435429 | Jazz Pharmaceuticals | Phase 3 | Recruiting | 2028-04-28Estimated |
| Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a AlloimmunizationNCT06435845 | Rallybio | Phase 2 | Terminated | 2025-10-01Actual |
| A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous UrticariaNCT06445023 | Celldex Therapeutics | Phase 3 | Active not recruiting | 2026-08-12Actual |
| Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or ObeseNCT06445075 | Scholar Rock, Inc. | Phase 2 | Completed | 2025-03-04Actual |
| A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)NCT06455202 | Celldex Therapeutics | Phase 3 | Active not recruiting | 2026-08-04Actual |
| A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)NCT06456580 | Vor Biopharma | Phase 3 | Active not recruiting | 2027-03Estimated |
| Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's DiseaseNCT06456593 | ABVX | Phase 2 | Recruiting | 2026-12Estimated |
| Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial CancerNCT06463028 | Faeth Therapeutics | Phase 2 | Recruiting | 2028-09Estimated |
| Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL CancerNCT06463665 | Genelux Corporation | Phase 2 | Recruiting | 2027-02Estimated |
| Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With HypoparathyroidismNCT06465108 | MBX Biosciences | Phase 2 | Completed | 2025-05-23Actual |
Trial details
- Registry ID
- NCT06391593
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06396065
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06400615
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06409663
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06411379
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06411899
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06412666
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT06413433
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06415344
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06418711
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06419205
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06420297
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06422351
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06423911
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06424444
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06429722
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06430385
- Phase
- Phase 1, Phase 2
Trial details
- Registry ID
- NCT06431776
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06431893
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06435221
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06435429
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06435845
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06445023
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06445075
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06455202
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06456580
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06456593
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06463028
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06463665
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06465108
- Phase
- Phase 2
Primary completion marks the end of data collection for the main study measures, not a results publication date.